SecBot SecBot

ARWR

ARROWHEAD PHARMACEUTICALS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0000879407 Biotech & Drug Discovery
$44.21 −3.57 (−7.47%)
Nov 16 4:00 PM ET · prev $47.78
Market cap
$6.7B
Mid cap
Consensus
Buy
95% Buy or better · 21 analysts
Median target
$105.50
+139% · range $73.00–126.00
1 year
+10.1%
from $40.15 · Nov 17
30 days
−22.8%
from $57.23
52-week range
$38.09–89.59
−51% from high · low Nov 20
Avg volume 20D
1.98M
Nov 9 spike 8.05M
Short interest
11.58M
≈8.2% of shares · +5.7%
Days to cover
8.5
at average volume
Insider net
−$3.7M
0 buyers · 5 sellers · 12 mo
New fund stakes
1
Q3 2026 13F · 2 exits
Filing reports
7
analyzed by SecBot
SecBot read BEARISH 6 reports · 90 days
Balance 2 bearish · 1 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 4/6

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $3.7M.

  • InstitutionsMIXED

    Q3 2026: 28 added (1 new), 30 trimmed or exited.

  • AnalystsBULLISH

    20 of 21 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +5.7% to 11.58M shares. 8.5 days to cover, ≈8.2% of shares.

  • TrendDOWNTREND

    29% below its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
2
exits
FundMoveSharesValue
MORGAN STANLEYADD1,835,149$120.1M
Pictet Asset Management Holding SAADD767,192$50.2M
BNP PARIBAS FINANCIAL MARKETSADD731,114$47.9M
FIRST TRUST ADVISORS LPTRIM441,326$28.9M
Connor, Clark & Lunn Investment Management Ltd.TRIM437,210$28.6M
Aberdeen Group plcADD413,104$27.0M
PRINCIPAL FINANCIAL GROUP INCTRIM367,315$24.0M
JANE STREET GROUP, LLCADD363,079$23.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 95% rate it Buy or better
Strong Buy7Buy13Hold1Sell0Strong Sell0
12-month targets · 14 analysts

Price is below the lowest target. Median implies +139%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 13, 2026RBC Capital
REITERATE
REITERATEOutperform
Nov 13, 2026Stifel
MAINTAIN
MAINTAINBuy
Oct 15, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Oct 15, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 8, 2026Citigroup
INITIATE
INITIATEBuy
Sep 1, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$3.7M
sold · 5 insiders
DateInsiderTypeValue
Aug 18, 2026
OLUKOTUN ADEOYE Y
Director
Aug 18, 2026
SELL$173.9K
Aug 18, 2026
PERRY MICHAEL S
Director
Aug 18, 2026
SELL$1.0M
Jun 15, 2026
Cohen Matthew Gregory
Director
Jun 15, 2026
AWARD11,882 sh
May 12, 2026
Lu Hongbo
Director
May 12, 2026
SELL$228.3K
Apr 23, 2026
Hamilton James C
Chief Medical Officer
Apr 23, 2026
SELL$750.0K
Apr 22, 2026
Apel Daniel Joseph
Chief Financial Officer
Apr 22, 2026
SELL$224.9K
Apr 22, 2026
Apel Daniel Joseph
Chief Financial Officer
Apr 22, 2026
SELL$627.9K
Apr 22, 2026
Apel Daniel Joseph
Chief Financial Officer
Apr 22, 2026
SELL$81.5K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
11,583,518
shares short
+5.7%
vs prior settlement
8.5
days to cover
≈8.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
Arrowhead Pharmaceuticals reported fiscal 2026 full-year revenue of $450.8M, down 45.6% from $829.4M in fiscal 2025…
8-K · Impact 6/10
Nov 12, 2026 Earnings result
ARWR Q4 2026 Earnings: EPS $-3.04 (-87.8% vs est)
Nov 5, 2026 SEC
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 9,307,349 shares of Arrowhead…
SC 13G/A · Impact 2/10
Nov 4, 2026 SEC
Arrowhead Pharmaceuticals refinanced its existing $400M senior secured term loan with Sixth Street, replacing a 15%…
8-K · Impact 5/10
Sep 30, 2026 Inst.
MORGAN STANLEY · ADD
1,835,149 shares ($120.1M)
Sep 30, 2026 Inst.
Pictet Asset Management Holding · ADD
767,192 shares ($50.2M)
Aug 18, 2026 Insider
OLUKOTUN ADEOYE Y sold 2,000 shares
Director @ $86.96 ($173.9K)
Aug 18, 2026 Insider
PERRY MICHAEL S sold 11,600 shares
Director @ $87.30 ($1.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
6 drugs tracked · Drug pipeline →
Recent

SecBot reports

7 filings · 1 bullish · 2 bearish · 1 mixed · 3 neutral
All ARWR filing & press-release reports (7)